AbbVie has formed a new collaboration with Valkai to enhance its artificial intelligence (AI) capabilities in clinical development. This partnership aims to improve efficiency in clinical research, accelerate insight generation, and reduce drug development timelines. By integrating Valkai's AI platform, AbbVie seeks to strengthen its data-driven innovation and expedite the delivery of new medicines to patients. This move reflects AbbVie's broader commitment to embedding AI across its operations to advance scientific progress and improve patient outcomes responsibly.
As of Sep 29, 2026 20:13 WIB, AbbVie Inc (ABBV) is trading at USD 266.00 on Pluang, showing a slight decrease of 0.15% over the day. The stock has a market capitalization of $470.55 billion and an enterprise value of $534.80 billion. Notably, the Pluang platform records a higher sell order activity at 71%, indicating cautious sentiment among investors at this time.
AbbVie Inc. is trading at all-time highs with a market cap over $500 billion, supported by robust 2026 guidance. The company's Q3 earnings are expected to outperform, mainly due to strong sales from immunology drugs Skyrizi and Rinvoq, projected to g...
AbbVie has submitted a Biologics License Application to the FDA for etentamig, a second-generation bispecific antibody T-cell engager for relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, etentamig demonstrated significant improv...
AbbVie will report its Q3 2026 earnings before market open on October 30, with shares up 28.55% year to date. Options pricing suggests a roughly 5% price move around the release, indicating high expectations. The company recently trimmed its full-yea...
